Study Number:	ANBL0531
NCT #:	NCT00499616
Dataset #:	D6
PMID #:	31386611
Comments:	Blanks represent missing data or not applicable for analyses. Data can be used to approximate published study findings, but exact reproduction of previous manuscripts may not be possible in some cases (e.g., when data must be modified for de-identification purposes or have undergone further data cleaning).

Variable Number	Variable Name	Variable Type	Label	Note
1	inss_stage_final_VTB	Char	INSS Stage	2-Stage 2A; 3-Stage 2B; 4-Stage 3; 5-Stage 4; 6-Stage 4S
2	risk_group_VTB	Char	Risk group	2-Intermediate; 3-High
3	mycn_VTB	Char	MYCN gene status	2-Not amplified
4	ploidy_category_VTB	Char	Ploidy category	Diploid; Hyperdiploid; Missing
5	diagnosis_VTB	Char	Morphology	
6	nbl_differentiation_N3_VTB	Char	Grade of differentiation	1-Totally undifferentiated; 2-Poorly differentiated; 3-Differentiating
7	histology_VTB	Char	International Neuroblastoma Pathology Classification (INPC)	1-Favorable; 2-Unfavorable
8	ldeSxIND_VTB	Char	Is patient symptomatic?	0-No; 1-Yes; 99-Unknown
9	age_at_diag_VTB	Num	Patient's age at diagnosis	Units=days
10	SEX_TXT_VTB	Char	Patient's gender	M=Male; F=Female
11	conep_loh_N3_VTB	Char	Chromosome arm 1p loss of heterozygosity	LOH; No LOH
12	cunb_11q_loh_N_3_VTB	Char	Chromosome arm 11q loss of heterozygosity	LOH; No LOH
13	biology	Char	Favorable or unfavorable based on histology, MYCN, and ploidy	Biology categories: Favorable Biology; Unfavorable Biology; Unknown Biology
14	efscens	Num	Neuroblastoma event flag	0=censor; 1=event

Study Number:	ANBL0531			
NCT #:	NCT00499616			
Dataset #:	D6			
PMID #:	31386611			
Comments:	Blanks represent missing data or not applicable for analyses. Data can be used to approximate published study findings, but exact reproduction of previous manuscripts may not be possible in some cases (e.g., when data must be modified for de-identification purposes or have undergone further data cleaning).			
Variable Number	Variable Name	Variable Type	Label	Note
15	scens	Num	Overall Survival event flag	0=censor; 1=death
16	dx_resection	Char	Degree of resection at diagnosis	biopsy only (<50%); Partial resection (50-90%); Complete/ near-complete resection (>90%). When conducting overall survival analysis, the partial resection and biopsy groups were combined and compared to the complete/near-complete resection category.
17	tx	Char	Treatment assignment	Baseline treatment with 2, 4, or 8 cycles
18	stratumperb1	Char	Stratum assignment	Group 2; Group 3; Group 4
19	age365_vtbc	Char	Age at diagnosis-1 year	<365 days old at diagnosis; >=365 days old at diagnosis
20	efstime	Num	Time to neuroblastoma event flag	Units=days
21	stime	Num	Time to Overall Survival flag	Units=days
22	dafe	Char	Death as a first event	Death as a first event; Death Not first Event
23	age_at_death	Num	Age at death	Units=days
24	surgcklistatdx	Char	Surgery information at diagnosis available	

Study Number:	ANBL0531
NCT #:	NCT00499616
Dataset #:	D6
PMID #:	31386611
Comments:	Blanks represent missing data or not applicable for analyses. Data can be used to approximate published study findings, but exact reproduction of previous manuscripts may not be possible in some cases (e.g., when data must be modified for de-identification purposes or have undergone further data cleaning).

Variable Number	Variable Name	Variable Type	Label	Note
25	age_at_dx3mo	Char	Age at diagnosis- 3 months	Age at DX LT 3 months; Age at DX 3-12 months; Age at DX GT 12 months
26	stg4infant	Char	Stage 4 infant	
27	row	Num	Subgroup within stratum	Subgrouping within stratum assignment as listed in Table 1. Not every patient fits a row description fully and in some cases, row assignment was decided by authors.
28	cyc_rcvd	Num	Number of cycles received	Cycles received (not assigned) on ANBL0531.
29	rcvd	Char	Therapy received	Planned; Less than planned; More than planned
30	Legcyc	Num	Number of cycles of therapy patient would be assigned on a predecessor trial	4=4 cycles; 8=8 cycles; 98=would not have been treated
31	much	Char	Patient treatment on ANBL0531 relative to predecessor trial	Less; More; Same
32	surgical_nephrectomy	Char	Surgery: Nephrectomy	
33	surgical_injury	Char	Surgery: Vascular or nerve injuries	

Study Number:	ANBL0531
NCT #:	NCT00499616
Dataset #:	D6
PMID #:	31386611
Comments:	Blanks represent missing data or not applicable for analyses. Data can be used to approximate published study findings, but exact reproduction of previous manuscripts may not be possible in some cases (e.g., when data must be modified for de-identification purposes or have undergone further data cleaning).

Variable Number	Variable Name	Variable Type	Label	Note
34	livetods	Char		Patients that would have been considered high risk prior to ANBL0531, but were treated as intermediate risk. Mentioned in Conclusion section of manuscript.
35	xrt	Char	Radiotherapy	
36	AML	Char	Acute myeloid leukemia	
37	salvagetx	Char	Salvage therapy flag	Used to identify the 27 patients that received CPM+TOPO.
38	surg_comp	Char	Surgical complications	Type of surgical complication experienced, among those listed in the manuscript.
39	deathdueto	Char	Cause of death	
40	PtResponse1TYPE	Char	Disease response	
41	ParaspnTmr	Char	Does patient have a paraspinal tumor?	Yes; No; NE (Not Evaluated); Not Available. Not intended to be used to identify patients with paraspinal tumors for the analysis.
42	NBLIspnExtn	Char	Does patient have neuroblastoma with intraspinal extension?	Yes; No; NE (Not Evaluated); Not Available. Not intended to be used to identify patients with paraspinal tumors for the analysis.

Study Number:	ANBL0531			
NCT #:	NCT00499616			
Dataset #:	D6			
PMID #:	31386611			
Comments:	Blanks represent missing data or not applicable for analyses. Data can be used to approximate published study findings, but exact reproduction of previous manuscripts may not be possible in some cases (e.g., when data must be modified for de-identification purposes or have undergone further data cleaning).			
Variable Number	Variable Name	Variable Type	Label	Note
43	lm	Char	Event type	(met)astatic; not met(astatic); Other/Unknown. Used to describe subgrouping of the 53 patients outlined in the Disease Progression and Death section.
44	Resp_post_8cyc_SUPPTBLA4	Char	Supplemental Table 4a: Response after 8 cycles	
45	Cycles_CPM_TOPO_SUPPTBLA4	Num	Supplemental Table 4a: No. of cycles CPM+TOPO	
46	Resp_post_CPM_TOPO_SUPPTBLA4	Char	Supplemental Table 4a: Response after CPM+TOPO	
47	Surg_sec_look_SUPPTBLA4	Char	Supplemental Table 4a: Second-Look Surgery	
48	Event_typ_SUPPTBLA4	Char	Supplemental Table 4a: Event	
49	Re_or_Prog_Dis_SUPPTBLA4	Char	Supplemental Table 4a: Relapse/Progressive Disease Site	
50	Time_to_event_SUPPTBLA4	Num	Supplemental Table 4a: Time to event	(Days since diagnosis)
51	CONSORT	Char	Details the follow-up section of the CONSORT diagram (Figure 1)	
52	secondDegRctnTp	Char	Diagnostic procedure performed at second look surgery	biopsy only (<50%); Partial resection (50-90%); Complete/near-complete resection (>90%)

Study Number:	ANBL0531			
NCT #:	NCT00499616			
Dataset #:	D6			
PMID #:	31386611			
Comments:	Blanks represent missing data or not applicable for analyses. Data can be used to approximate published study findings, but exact reproduction of previous manuscripts may not be possible in some cases (e.g., when data must be modified for de-identification purposes or have undergone further data cleaning).			
Variable Number	Variable Name	Variable Type	Label	Note
53	secondsurg	Char	Second look surgery flag	
54	surgcompPT	Char	Flag for patients with surgery related complication	
55	SURG_PR	Char	Required surgery to achieve PR or better of the primary site	Conclusion section of manuscript specifies 90 patients that required surgery to achieve disease response.
56	CONSORT_EXCLUDE	Char	Exclusion from the analysis	Identifies who is excluded from the analysis, as outlined in the CONSORT diagram and for what reason.
57	xtracycles83	Char	Flag to identify the patients who received extra cycles of chemotherapy among those who are in Stage 2a, 2b or 3.	
58	spinal_tumors	Char	Spinal tumor flag	
59	cpmtopo_relapse	Char	Flag to identify the patients that experienced relapse after CPM plus TOPO	Used in the Survival According to Initial Group Assignment and 1p36/11q23 Allelic Status section.
60	tbl1_biologic_features	Char	Features: Characteristic of subgroup assignment	Description of biologic features in Table 1.
61	usi	Char	ID	Patient identifier and primary key